Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2021 | Association between severe irAEs and PDCD1 polymorphism in mRCC

Kazuyuki Numakura, MD, PhD, Akita Graduate School of Medicine, Akita, Japan, discusses the association of severe immune-related adverse events (irAEs) and PD-1 protein-coding gene (PDCD1) polymorphism in patients with metastatic renal cell carcinoma (mRCC) who are treated with nivolumab, a novel anti-PD-1 antibody, which is used as a standard therapy for patients with mRCC, either as a monotherapy or in combination with ipilimumab. Data from 70 patients with mRCC who were treated with nivolumab or nivolumab plus ipilimumab was analyzed. Dr Numakura reports that PDCD1 polymorphism was not found to be associated with clinical outcomes of nivolumab therapy, however PDCD1 PD-1.6 (rs10204545) polymorphism was associated with severe and multiple irAEs. This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.